Source-grounded facts extracted from DiaMedica Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
DiaMedica Therapeutics Inc. shareholders approved Amendment and Restatement of the Amended and Restated 2019 Omnibus Incentive Plan at the 2026-05-20 meeting.
“Voting Proposal Four – Amendment and Restatement of the Amended and Restated 2019 Omnibus Incentive Plan The voting proposal to approve an amendment to the Company’s Amended and Restated 2019 Omnibus Incentive Plan to increase the number of shares available under the plan by 3,500,000 shares was approved based on the following voting results:”
Shareholder Votes
DiaMedica Therapeutics Inc. shareholders approved Advisory Vote to Approve of Executive Compensation at the 2026-05-20 meeting.
“Voting Proposal Three – Advisory Vote to Approve of Executive Compensation The voting proposal to approve, on an advisory (non-binding) basis, the Company’s executive compensation was approved based on the following voting results:”
Shareholder Votes
DiaMedica Therapeutics Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-05-20 meeting.
“Voting Proposal Two – Ratification of Independent Registered Public Accounting Firm The voting proposal to appoint Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 and authorize the Board to fix the Company’s independent registered public accounting firm’s remuneration was approved based on the following voting results:”
Shareholder Votes
DiaMedica Therapeutics Inc. shareholders approved Election of Directors at the 2026-05-20 meeting.
“Voting Proposal One - Election of Directors The seven director nominees, all incumbent directors, proposed by the Board were re-elected to serve as members of the Board until the next annual general meeting of shareholders and until their respective successors are duly elected and qualified based on the following voting results:”
Earnings Releases
DiaMedica Therapeutics Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $10.0 million for the three months ended March 31, 2026, compared to $7.7 million for the three months ende.
“Net loss was $10.0 million for the three months ended March 31, 2026, compared to $7.7 million for the three months ended March 31, 2025.”
Earnings Releases
DiaMedica Therapeutics Inc. reported financial results for the year ended December 31, 2025.
“On March 30, 2026, DiaMedica Therapeutics Inc. (the "Company") announced its consolidated financial results for the year ended December 31, 2025.”
Richard Pilnik departed as Director at DiaMedica Therapeutics Inc..
“On February 28, 2025, Richard Pilnik, who has been a member of the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), for over 15 years, informed the Company of his decision to retire and not to stand for re-election at the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”).”
Daniel J. O'Connor was appointed as Director at DiaMedica Therapeutics Inc..
“On February 20, 2025, the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel J. O’Connor to the Board, effective immediately.”
Rebekah de Vitry Fries changed role as other_named_officer at DiaMedica Therapeutics Inc..
“Following the departure of Ms. Daves, Rebekah de Vitry Fries, who currently serves as DiaMedica’s Vice President of Clinical Operations, will assume leadership of DiaMedica’s clinical operations.”
Julie VanOrsdel Daves resigned as Senior Vice President, Clinical Development Operations at DiaMedica Therapeutics Inc..
“Julie VanOrsdel Daves MSHS, CCRP notified us of her resignation as Senior Vice President, Clinical Development Operations of DiaMedica Therapeutics Inc. (“DiaMedica”), effective as of April 18, 2024, for personal reasons.”
Earnings Releases
DiaMedica Therapeutics Inc. reported financial results for the year ended December 31, 2023.
“On March 19, 2024, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the year ended December 31, 2023.”
Earnings Releases
DiaMedica Therapeutics Inc. reported financial results for three and nine-month periods ended September 30, 2023.
“On November 13, 2023, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the three and nine-month periods ended September 30, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and the information set forth therein is incorporated herein by reference and constitutes a part of Item 2.02 of this report.”
Jordan Dubow was appointed as Chief Medical Officer at DiaMedica Therapeutics Inc..
“To replace Dr. Gruis immediately on an interim basis while DiaMedica completes its search for a permanent Chief Medical Officer, DiaMedica has engaged as an independent consultant, Jordan Dubow, M.D.”
Kirsten Gruis resigned as Chief Medical Officer at DiaMedica Therapeutics Inc..
“On September 3, 2023, Kirsten Gruis, M.D. resigned from her position as Chief Medical Officer of DiaMedica Therapeutics Inc. (“DiaMedica” or the “Company”), effective as of August 31, 2023”
Material Agreements
DiaMedica Therapeutics Inc. entered into Securities Purchase Agreement with accredited investors, including certain existing stockholders and certain directors and officers valued at gross proceeds of $37.5 million (effective 2023-06-21).
“entered into securities purchase agreements (the “Securities Purchase Agreement”) with accredited investors, including certain existing stockholders and certain directors and officers (collectively, the “Purchasers”), pursuant to which the Company agreed to issue 11,011,406 common shares, no par value, of the Company (collectively, the “Shares”), in a private placement (the “Private Placement”).”
Governance Changes
DiaMedica Therapeutics Inc.: Shareholders approved amendments to Articles to enhance director nomination procedures and give board authority to fix number of directors (effective 2023-05-17).
“At an Annual General and Special Meeting of Shareholders held on May 17, 2023, the shareholders of DiaMedica Therapeutics Inc. (the “Company”) approved two amendments to the Company’s Articles (collectively, the “Articles Amendments”), one of which enhanced the procedural mechanics and disclosure requirements relating to director nominations made by the Company’s shareholders in order to make reference to the universal proxy rules of the U.S. Securities and Exchange Commission (the “SEC”), ensure an orderly nomination and election process, and ensure that a dissident’s interests are fully disclosed to the Company and its shareholders, and the other which provided that only the Board of Directors (the “Board”) may fix the number of directors of the Company.”
Shareholder Votes
DiaMedica Therapeutics Inc. shareholders approved Approval of Amendment to Articles Regarding Board Authority to Fix Number of Directors at the 2023-05-17 meeting.
“Voting Proposal Four – Approval of Amendment to Articles Regarding Board Authority to Fix Number of Directors. The voting proposal to approve an amendment to the Company’s Articles regarding the Board’s authority to fix the number of directors was approved by the following final voting results: Votes For Votes Against Broker Non-Votes 3,403,969 1,527,464 8,408,839”
Shareholder Votes
DiaMedica Therapeutics Inc. shareholders approved Approval of Amendment to Articles Regarding Director Nominations by Shareholders at the 2023-05-17 meeting.
“Voting Proposal Three – Approval of Amendment to Articles Regarding Director Nominations by Shareholders. The voting proposal to approve an amendment to the Company’s Articles regarding director nominations by shareholders was approved by the following final voting results: Votes For Votes Against Broker Non-Votes 4,520,227 411,207 8,408,839”
Shareholder Votes
DiaMedica Therapeutics Inc. shareholders approved Appointment of Independent Registered Public Accounting Firm and Authorization to Fix Remuneration at the 2023-05-17 meeting.
“Voting Proposal Two - Appointment of Independent Registered Public Accounting Firm and Authorization to Fix Remuneration. The voting proposal to appoint Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 and authorize the Board to fix the Company’s independent registered public accounting firm’s remuneration was approved by the following final voting results: Votes For Votes Withheld Broker Non-Votes 13,051,215 289,058 0”
Shareholder Votes
DiaMedica Therapeutics Inc. shareholders approved Election of Directors at the 2023-05-17 meeting.
“Voting Proposal One - Election of Directors. The six director nominees proposed by the Board were elected to serve as members of the Board until the next annual general meeting of shareholders and until their respective successors are duly elected and qualified by the following final voting results: Votes For Votes Withheld Broker Non-Votes Richard Pilnik 4,574,007 357,427 8,408,839 Michael Giuffre, M.D. 4,665,154 266,280 8,408,839 Tanya Lewis 4,627,912 303,522 8,408,839 James Parsons 4,673,229 258,205 8,408,839 Rick Pauls 4,658,601 272,833 8,408,839 Charles Semba, M.D. 4,678,225 253,209 8,408,839”
Earnings Releases
DiaMedica Therapeutics Inc. reported financial results for the quarter ended March 31, 2023.
“On May 15, 2023, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the quarter ended March 31, 2023.”
Earnings Releases
DiaMedica Therapeutics Inc. reported financial results for for the year ended December 31, 2022.
“On March 28, 2023, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the year ended December 31, 2022.”
Tanya N. Lewis was appointed as Member of Compensation Committee at DiaMedica Therapeutics Inc..
“On and effective March 9, 2023, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Ms. Lewis as a member of the Compensation Committee of the Board.”
Tanya N. Lewis was appointed as Director at DiaMedica Therapeutics Inc..
“the Board of Directors (the “Board”) of the Company appointed Tanya N. Lewis to the Board, effective March 1, 2023.”
Tanya N. Lewis was appointed as director at DiaMedica Therapeutics Inc..
“To fill the vacancy created by Ms. Burroughs’s resignation, on March 1, 2023, the Company’s Board of Directors (the “Board”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Tanya N. Lewis to the Board, effective immediately, to fill the vacancy created by Ms. Burroughs’s resignation.”
Amy L. Burroughs resigned as director at DiaMedica Therapeutics Inc..
“On March 1, 2023, Amy L. Burroughs resigned as a director of DiaMedica Therapeutics Inc.”
Earnings Releases
DiaMedica Therapeutics Inc. reported financial results for the three and nine months ended September 30, 2022.
“On November 9, 2022, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the three and nine months ended September 30, 2022.”
Harry Alcorn, Jr. resigned as Senior Vice President of Clinical Operations at DiaMedica Therapeutics Inc..
“On May 23, 2022, Harry Alcorn, Jr., Pharm.D., Senior Vice President of Clinical Operations of DiaMedica Therapeutics Inc. (the “Company”), resigned as an officer and employee of the Company and its subsidiaries, effective immediately.”
Charles Semba, M.D. was elected as director at DiaMedica Therapeutics Inc..
“the Company’s shareholders elected each of Amy Burroughs and Charles Semba, M.D. as a director of the Company effective immediately.”
Amy Burroughs was elected as director at DiaMedica Therapeutics Inc..
“the Company’s shareholders elected each of Amy Burroughs and Charles Semba, M.D. as a director of the Company effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.